NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.2 Drugs affecting the immune response > 8.2.4 Other immunomodulating drugs > Nivolumab for previously treated squamous non-small-cell lung cancer - NICE TAG TA483

Nivolumab for previously treated squamous non-small-cell lung cancer - NICE TAG TA483

1.1 Nivolumab is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic squamous non-small-cell lung cancer in adults after chemotherapy, only if:

  • nivolumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease progression, and

  • the conditions in the managed access agreement are followed.

1.2 This recommendation is not intended to affect treatment with nivolumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/ta483

Site by Devopa
© Copyright 2019 NHS. All rights reserved.